Cholesterol Lowering Effects of Low-dose Statins in Korean Patients.
- Author:
Jee Eun KWON
1
;
Young KIM
;
Seonghyup HYUN
;
Hoyoun WON
;
Seung Yong SHIN
;
Kwang Je LEE
;
Sang Wook KIM
;
Tae Ho KIM
;
Chee Jeong KIM
Author Information
- Publication Type:Original Article
- Keywords: 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors; Hypercholesterolemia; LDL Cholesterol
- MeSH: Cholesterol*; Cholesterol, LDL; Coenzyme A; Dyslipidemias; Education; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors*; Hypercholesterolemia; Lipoproteins; Lovastatin; Oxidoreductases; Pravastatin; Prospective Studies; Simvastatin; Atorvastatin Calcium; Rosuvastatin Calcium
- From:Journal of Lipid and Atherosclerosis 2014;3(1):21-28
- CountryRepublic of Korea
- Language:Korean
- Abstract: OBJECTIVE: The aim of this study is to compare cholesterol lowering effects of low dose 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) in Korean patients. METHODS: A total of 909 consecutive patients were enrolled prospectively according to the criteria of National Cholesterol Education Program guidelines. Lipid profiles were obtained before and 2 months after statin therapy. RESULTS: Atorvastatin 10 mg (n=260), lovastatin 20 mg (n=145), pitavastatin 2 mg (n=80), pravastatin 20 mg (n=28), rosuvastatin 5 mg (n=145), and simvastatin 20 mg (n=208) reduced low density lipoprotein (LDL) cholesterol by -41.8+/-11.0%, -33.8+/-12.8%, -39.3+/-10.8%, -31.5+/-8.9%, -48.8+/-12.3%, and -42.8+/-13.5%, respectively. LDL cholesterol less than 130 mg/dL was achieved in 90.3%, 76.9%, 88.5%, 85.2%, 97.2%, and 94.2%, respectively. The reduction of LDL cholesterol by 30% or more was obtained in 84.4%, 60.7%, 81.6%, 63.0%, 93.0%, and 83.5%, respectively. LDL cholesterol less than 70 mg/dL or the reduction by 50% or more was observed in a small portion of patients and was variable according to the different types of statins. CONCLUSION: A low dose statin was enough to manage dyslipidemia in most Korean patients with low to moderate risks and was even effective in a subpopulation of high risk patients.
